Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 9, 2008 - Biogen Idec (NASDAQ: BIIB) announced today that its Phase II trial of baminercept (BG9924, LT(beta)R-Ig) in rheumatoid arthritis (RA) patients who have had an inadequate response to conventional therapy with a disease-modifying antirheumatic drug (DMARD) did not meet its primary endpoint. The primary endpoint was defined as the proportion of baminercept-treated patients who achieved an ACR50 response, a standard measure of disease improvement in RA, compared to placebo at 14 weeks. The study also did not meet any of the pre-specified secondary endpoints. Biogen Idec will continue to analyze the study results and will submit the data for presentation at an upcoming medical meeting. Based on these results as well as preliminary data from a Phase II trial of baminercept in RA... [read full story]